Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Inclusion Criteria:

* Females at least 18 years of age with ovarian carcinoma who are one of the following:

  * Newly diagnosed with ovarian cancer and chemotherapy naïve, or
  * Post a single previous course of chemotherapy, with a 3-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit, or
  * Post two or more previous courses of chemotherapy with a 6-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit.
* Must be scheduled for a course of combination chemotherapy consisting of gemcitabine and cisplatin or gemcitabine and carboplatin to be administered in 21-day cycles
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
* Adequate bone marrow, renal, and hepatic functions as measured by standard chemistry and hematology blood tests
* Adequate blood coagulation parameters as measured by standard blood tests for coagulation

Exclusion Criteria:

* Any clinical or laboratory abnormality greater than Grade 2 toxicity (NCI criteria), with the exception of laboratory parameters specified in the inclusion criteria
* Significant unstable cardiovascular disease
* Uncontrolled high blood pressure
* Current use of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II antagonists
* Evidence of metastatic disease to the bone
* Metastatic disease to the CNS requiring treatment or radiation therapy
* Uncontrolled infection(s)
* Radiation therapy or chemotherapy (except as specified in the inclusion criteria) within the previous 5 years
* Concurrent use of hematopoietic or erythropoietic agents